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developed with a time horizon of 40 years. Transition probabil-
ities for macrovascular and microvascular complications were
drawn from the UKPDS 68 Outcomes equations. Direct costs
and quality of life (EQ5D) were derived from published sources
and the HODaR database respectively; costs and beneﬁts were
discounted annually at 3.5%. This model was adapted for Type
2 patients switched from NPH to glargine identiﬁed from 
the THIN database, a UK primary care database including
2,335,667 active patients recorded over 15 years from 211 prac-
tices. Analysis was conducted on a total of 181 patients with
data for the 12 month period prior to and post switch to
glargine; the primary outcome measure was Hba1c change.
RESULTS: The median age at switch from NPH was 71 with
mean duration of T2DM of 9.2 years. Baseline HbA1c was
8.79% and patients switching to glargine showed a signiﬁcant
reduction in HbA1c of 0.67%(p = 0.00384) between switch to
glargine and 12 months post glargine initiation. Incorporating
this into a simulated cohort of 10,000 patients followed over a
40 year time horizon translated into 150 fewer cardiovascular
events. Average cost per patient was ≤4338 and ≤3370 for
glargine and NPH respectively, providing discounted quality
adjusted life years (QALYs) of 4.96 and 4.86 respectively; result-
ing in a discounted incremental cost effectiveness ratio (ICER)
of ≤9200 per QALY. CONCLUSION: Based on UK real life
observational data, switching to basal insulin in type 2 DM
patients from NPH to glargine is cost-effective; with a corre-
sponding ICER within accepted thresholds for cost-effective
treatments.
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OBJECTIVES: The purpose of this study was to evaluate the cost
effectiveness (cost utility) of insulin glargine in the UK for people
with Type 1 diabetes mellitus (T1DM) using observational data
in patients continuing on NPH versus those switching from NPH
to insulin glargine. METHODS: A discrete event simulation
model was developed with a time horizon of 40 years. Transi-
tion probabilities for progression to microvascular complications
were derived from the DCCT (Diabetes Control and Complica-
tions Trial) with cardiovascular events modelled via the Fram-
ingham equations. Direct costs and quality of life (EQ5D) were
derived from published sources and the HODaR database
respectively; costs and beneﬁts were discounted annually at
3.5%. The model was adapted to the proﬁle of T1DM patients
switched from NPH to glargine identiﬁed via the THIN database
(The Health Improvement Network), a UK primary care data-
base including 2,335,667 active patients recorded over 15 years.
Analysis was conducted on a total of 466 patients with data for
the 12 month period prior to, and post switch; the primary
outcome measure of Hba1c change. RESULTS: The median age
of patients switched from NPH to glargine was 33 years with
mean duration of T1DM of 8.1 years. Baseline HbA1c was
8.71% and patients switching to glargine showed a reduction in
HbA1c of 0.27% between switch and 12-months post initiation.
Over 40 years, in a simulated cohort of 10,000 there were 523
fewer fatal microvascular complications and, on average, 1 less
microvascular complication per patient in those receiving
glargine compared to NPH. The discounted incremental cost
effectiveness ratio (ICER) was £6527 per quality adjusted life
year (QALY) gained. CONCLUSION: Based on UK real life
observational data, switching to basal insulin in type 1 DM
patients from NPH to glargine is cost-effective; with a corre-
sponding ICER well within accepted thresholds for cost-effective
treatments.
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OBJECTIVES: Outcomes in type 2 diabetes patients can differ
based on the antidiabetic medication that is used. Thiazolidine-
diones (TZD) are a newer class of agents used for type 2 dia-
betes treatment. Previously, no study has compared health care
utilization associated with the two TZDs on the market. The
objective of this study was to compare health care utilization
between two TZDs used by Medicaid-enrolled patients with type
2 diabetes. METHODS: This was a retrospective data analysis
comparing cohorts of patients with type 2 diabetes starting a new
antidiabetic medication for hospitalizations, emergency room
visits, outpatient visits, and health care costs. A total of 660
patients starting rosiglitazone between July 1, 2001 to June, 30,
2002 were compared to 1045 patients staring pioglitazone
during the same period. The patients were followed up for 30
months to examine the difference in health care utilization over
time. Multivariate regression techniques were employed for com-
parisons between different antidiabetic therapies. RESULTS:
Multivariate analysis showed that rosiglitazone group was asso-
ciated with almost 12% decrease in the mean number of hospi-
talizations, and 10 % decrease in the mean number of emergency
room visits, and a 7.3% decrease in total health care costs 
as compared to the pioglitazone group (all p < 0.05). CON-
CLUSION: Introduction of rosiglitazone was associated with
decreased number of hospitalizations, emergency room visits,
and total health care costs compared to pioglitazone. The uti-
lization of oral antidiabetic agents, with documented clinical and
economic beneﬁts, should continue to be advocated to reduce
avoidable medical care utilization, and improve patient out-
comes in this population.
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OBJECTIVES: Diabetes is the sixth leading cause of death in the
United States, and its prevalence has been increasing. The annual
cost of this illness to society reached close to $100 billion in
1999. The objective of this study is to analyze the trends of price
and utilization of oral anti-diabetic medications in U.S. state
Medicaid programs. METHODS: Oral anti-diabetic drugs
include ﬁrst- and second-generation sulfonylureas, α-glucosidase
inhibitors, biguanides, thiazolidinediones, meglitinides, and
combination drugs. Data were taken from the national Medic-
aid pharmacy claims databases for 1991 to 2005, provided by
the Centers for Medicare & Medicaid Services. Descriptive time-
series analysis was used to assess quarterly prescription numbers,
amount of reimbursement, and cost per prescription. RESULTS:
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The total reimbursement for anti-diabetic drugs in U.S. Medic-
aid programs increased from $90.7 million in 1991 to $1.1
billion in 2005. The number of prescriptions increased dramat-
ically from 4.1 million in 1991 to 18.2 million in 2005. The cost
per prescription for brand-name drugs increased over time as
well. The relatively expensive drugs in 2005 were Actos ($169),
Avandia ($133), Avandamet ($150), Prandin($113), and Starlix
($103). The total number of prescriptions for the ﬁrst-generation
sulfonylureas dropped from 1.1 million in 1991 to 292,000 in
2005, while the number of prescriptions for other classes
increased over the years. For example, the number of prescrip-
tions for biguanides increased from 39,849 in 1995 to 5.7
million in 2005, the number of thiazolidinedione prescriptions
increased from 323,581 in 1997 to 4.5 million in 2005, and the
number of meglitinide prescriptions increased from 30,790 in
1998 to 425,516 in 2005. CONCLUSION: Increased expendi-
ture for oral anti-diabetic drugs was caused by both increased
price and utilization. When the generic drugs metformin, glip-
izide, and glyburide were introduced to the market, the use of
their brand-name counterparts decreased dramatically due to
Medicaid’s policies encouraging generic substitution.
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OBJECTIVES: The American Diabetes Association recommends
treating diabetes patients to a target hemoglobin A1c level of 7%
or less. Our objective was to examine the inﬂuence of A1c test
results on decisions to initiate exogenous insulin supplementa-
tion in Type 2 diabetes. METHODS: A database of clinical lab-
oratory results linked to health plan claims (MarketScan Lab)
was used to identify patients with a diagnosis of Type 2 diabetes.
Their ﬁrst A1c test result between July 2003 and June 2005 was
identiﬁed and patients were classiﬁed as at target (less than 7),
above target (7–9), or poorly controlled (>9). The study sample
was restricted to patients who had 6 months of claims history
prior to and 6 months after the index test, and who received only
oral antidiabetes therapy during the pre-test period. Addition of
insulin to the regimen within 6 months after the test was
assessed. RESULTS: A total of 4836 patients were identiﬁed,
including 2450 (51%) who were at target, 1567 (32%) above
target, and 819 (17%) poorly controlled. Insulin was added to
the regimen of 12.9% of patients with poor control, 4.3% of
those above target, and 1.5% of those at target (p < 0.00001).
Among poorly controlled patients insulin was added in 22.0%
of patients already on 3 oral medications, 12.6% of those with
2 oral medications, and 8.6% of those with 1 oral medication
(p < 0.001). A1c test result and prior oral medication use
remained signiﬁcant predictors of insulin supplementation after
controlling for demographic variation. CONCLUSION: High
levels of A1c indicating poor glycemic control led some patients
with Type 2 diabetes to initiate insulin supplementation, par-
ticularly those already receiving multiple oral medications.
However, poorly controlled patients were still most likely to
remain on oral therapy only, even if they were already using 3
or more medications.
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OBJECTIVES: The purpose of this study was to assess the
impact of patient and physician education on Hemoglobin A1c
(HbA1c) control in diabetes patients with concomitant hyper-
tension. METHODS: The analysis was based on a subset of
those enrolled in the Baltimore Partnership Programs to Reduce
CVD Disparities project, with one year of follow-up. Patients
and their physicians were randomly assigned to either interven-
tion or control group, in a 2X2 nested case control factorial
design. Patients and physicians participated in educational ses-
sions. We calculated the change in HbA1c value, from baseline,
to one year follow-up. Multiple regression was used to assess the
effects of interventions on HbA1c change adjusting for age, race,
gender and hypertension. RESULTS: Out of the study cohort of
114 patients, most were African American (96%) and female
(62%). Mean baseline HbA1c values were higher among males
vs. females (8.7% vs. 8.6%), African Americans vs. Caucasians
(8.7% vs. 8.15%), Intervention patients vs. control patients
(9.15% vs. 8.28%), and patients of Intervention vs. control
physicians (8.94% vs.8.33%). The drop in the HbA1c values
was greater among intervention patients (−0.6 vs. 0.2) and
patients of intervention physicians (−0.32 vs. 0.01). After con-
trolling for age, race, gender and hypertension, the drop in
HbA1c in the patient intervention group was greater than the
control and the drop in HbA1c in the patients of intervention
physicians was greater than the control though statistically non-
signiﬁcant. CONCLUSION: In this patient sample, greater drop
in HbA1c is seen among the intervention patients and patients
of Intervention physicians. These results highlight the inﬂuence
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OBJECTIVES: The Diabetes Symptom Checklist-Revised
(DSCR) is a 34-item, 7-subscale instrument designed to provide
a comprehensive measure of diabetes-associated symptoms.
When evaluating antihyperglycemic medications in a clinical trial
however, only those symptoms affected by ﬂuctuations in
glycemic control (e.g., hyperglycemia) would be expected to
change. Therefore, the objective of this study was to validate the
DSC-R Cognitive Distress, Fatigue, Hyperglycemia, and Hypo-
glycemia subscales as individual measures of symptom groups to
be targeted in clinical trials of antihyperglycemic medications.
METHODS: In two clinical trials evaluating antihyperglycemic
medications (Study 1: insulin therapy in 137 patients with type
1 diabetes; Study 2: oral therapy in 150 patients with type 2 dia-
betes), participants were administered the DSC-R at several time
periods including screening, baseline and endpoint. To conﬁrm
the factorial validity of the subscales, a promax factor analysis
